CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years ...

Retrieved on: 2022-01-31 06:29:07

Tags for this article:

Medical specialties

Clinical medicine

Health care

Monoclonal antibodies

Regeneron Pharmaceuticals

Atopic dermatitis

Corticosteroid

Aspergillosis

Dupixent Regeneron Pharmaceuticals Inc.

Alirocumab

Click the tags to see associated articles and topics

CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years .... View article details on HISWAI: https://www.prnewswire.com/news-releases/chmp-recommends-approval-of-dupixent-dupilumab-for-children-aged-6-to-11-years-with-severe-asthma-with-type-2-inflammation-301470938.html

Excerpt

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, ...

Article found on: www.prnewswire.com

View Original Article